Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02NUT
|
|||
| Former ID |
DIB018027
|
|||
| Drug Name |
KU-60019
|
|||
| Synonyms |
KU-60019; 925701-49-1; ku60019; 925701-46-8; KU 60019; UNII-IAN358A69K; IAN358A69K; CHEMBL2140173; 2-[(2S,6R)-2,6-dimethylmorpholin-4-yl]-N-[5-(6-morpholin-4-yl-4-oxopyran-2-yl)-9H-thioxanthen-2-yl]acetamide; C30H33N3O5S; 2-((2S,6R)-2,6-dimethylmorpholino)-N-(5-(6-morpholino-4-oxo-4H-pyran-2-yl)-9H-thioxanthen-2-yl)acetamide; 2-[(2R,6S)-2,6-Dimethylmorpholin-4-yl]-N-{5-[6-(morpholin-4-yl)-4-oxo-4H-pyran-2-yl]-9H-thioxanthen-2-yl}acetamide; MLS006011020; cc-509; SCHEMBL3681453; GTPL8041; EX-A658; DTXSID00580453; AOB3627
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Non-small-cell lung cancer [ICD-11: 2C25.Y] | Clinical trial | [1] | |
| Structure |
 |
Download2D MOL
|
||
| Formula |
C30H33N3O5S
|
|||
| Canonical SMILES |
CC1CN(CC(O1)C)CC(=O)NC2=CC3=C(C=C2)SC4=C(C3)C=CC=C4C5=CC(=O)C=C(O5)N6CCOCC6
|
|||
| InChI |
1S/C30H33N3O5S/c1-19-16-32(17-20(2)37-19)18-28(35)31-23-6-7-27-22(13-23)12-21-4-3-5-25(30(21)39-27)26-14-24(34)15-29(38-26)33-8-10-36-11-9-33/h3-7,13-15,19-20H,8-12,16-18H2,1-2H3,(H,31,35)/t19-,20+
|
|||
| InChIKey |
SCELLOWTHJGVIC-BGYRXZFFSA-N
|
|||
| CAS Number |
CAS 925701-49-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
22425440, 26559769, 33336771, 104253219, 124757344, 124939250, 124939251, 125164148, 136348256, 136367551, 139585005, 141119833, 152258381, 160647218, 162011850, 162037670, 162202608, 163907986, 172914014, 174007027, 174531520, 184816792, 223704675, 229676619, 241178078, 241376848, 242559685, 245933171, 249565721, 249820233, 252088587, 252109980, 252157848, 252450576
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | ATM serine/threonine kinase (ATM) | Target Info | Inhibitor | [1] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion. Mol Cancer Ther. 2009 Oct;8(10):2894-902. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.